LIFERIVER(SH:688317)2026-02-27 08:10Financial Performance - Total revenue for 2025 was CNY 12,491.36 million, a decrease of 30.08% compared to the previous year[3] - Net profit attributable to the parent company was CNY -3,430.38 million, a reduction in loss of CNY 9,315.83 million year-on-year[5] - Basic earnings per share were CNY -0.19, an improvement from CNY -0.67 in the previous year[3] Assets and Equity - Total assets at the end of the reporting period were CNY 376,367.96 million, a decrease of 0.69% from the beginning of the period[5] - Equity attributable to the parent company decreased by 7.92% to CNY 334,879.63 million[4] Revenue Drivers - The decline in revenue was primarily due to the implementation of centralized procurement policies, which led to lower sales prices[6] - The VAT rate for self-produced reagent products was adjusted to 13%, impacting revenue[7] Cost Management - The company implemented cost control measures, resulting in a reduction of asset impairment losses year-on-year[6] Strategic Focus - The company is focusing on product research and development to enhance market competitiveness[6] Data Integrity - There are no significant uncertainties affecting the accuracy of the financial data reported[10]